RxDoctor Payments DataLook up a doctor →

David Bartels, DO

Hematology & Oncology · Coeur D Alene, IDNPI 1245492768

Payments from drug & device makers

$10,731in general payments, 2019–2025

Across 538 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$977
  • Pfizer$924
  • E.r. Squibb & Sons, L.L.C.$741
  • Merck$671
  • Bristol Myers Squibb$621
  • Amgen$576
  • plus $6K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis61$977
Pfizer62$924
E.r. Squibb & Sons, L.L.C.42$741
Merck32$671
Bristol Myers Squibb41$621
Amgen(2 entities)15$576
Seagen Inc.16$479
Johnson & Johnson(2 entities)28$467
AstraZeneca22$420
AbbVie14$360
Eisai Inc.13$266
Genentech USA, Inc.14$263
Lilly USA, LLC11$229
GSK12$227
Array Biopharma Inc16$208
Sanofi10$202
Bayer10$202
ASD Specialty Healthcare, LLC2$187
Exelixis Inc.9$184
Boehringer Ingelheim7$184
Astellas Pharma US Inc5$181
AVEO Pharmaceuticals, Inc.6$174
Gilead(2 entities)8$163
Takeda Pharmaceuticals U.S.A., Inc.8$129
Dendreon Pharmaceuticals LLC4$119
Daiichi Sankyo Inc.2$107
Springworks Therapeutics, Inc.4$100
Octapharma USA, Inc.1$92
Pharmacyclics LLC, An Abbvie Company5$90
Regeneron Healthcare Solutions, Inc.3$80
Karyopharm Therapeutics Inc.4$80
Iovance Biotherapeutics, Inc.2$66
Myriad Genetic Laboratories, Inc.3$65
Cardinal Health 108 LLC2$61
Taiho Oncology, Inc.2$53
Agios Pharmaceuticals, Inc.3$51
Blueprint Medicines Corporation2$50
Rigel Pharmaceuticals, Inc.3$47
Sun Pharmaceutical Industries Inc.2$45
Sanofi-aventis U.S. LLC2$38
Mirati Therapeutics, Inc.2$35
Helsinn Therapeutics (U.S.), Inc.2$33
Incyte Corporation2$33
EMD Serono, Inc.2$33
Beigene USA, Inc.2$32
CTI Biopharma Corp.1$29
Janssen Scientific Affairs, LLC1$28
Fennec Pharmaceuticals, Inc.1$24
Beone Medicines USA, Inc.1$23
Jazz Pharmaceuticals Inc.1$22
Genmab U.S., Inc.1$22
Adaptive Biotechnologies Corporation1$21
Fresenius Kabi USA, LLC1$21
Verastem, Inc.1$21
Stemline Therapeutics Inc.1$20
Aurobindo Pharma USA, Inc.1$19
Pharmacosmos Therapeutics Inc.1$19
Clovis Oncology, Inc.1$18
Sirtex Medical Inc1$16
Acrotech Biopharma Inc.1$16

How this compares

$10,731 in reported general payments places this provider in the 55th percentile of 34 hematology & oncology providers in Idaho.

See all hematology & oncology providers in Idaho →

Medicare billing

Part B allowed, 2024
$9,348,996
Medicare patients
753
Services billed
303,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Coeur D Alene

See the full list for Idaho →

Where these figures come from

Is this you, or does something look wrong? →